LICENSE AGREEMENTS (Details) (USD $)	12 Months Ended					0 Months Ended			12 Months Ended		0 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012 License agreements GE Healthcare UK Limited	Dec. 31, 2011 License agreements GE Healthcare UK Limited	Dec. 31, 2010 License agreements GE Healthcare UK Limited	Dec. 03, 2012 License agreements Angiochem item	Jan. 05, 2011 License agreements Angiochem	Dec. 06, 2010 License agreements Angiochem	Dec. 31, 2012 License agreements Angiochem item	Dec. 31, 2010 License agreements Angiochem	Dec. 05, 2012 License agreements TA Sciences
LICENSE AGREEMENTS
Revenues from collaborative agreements	$ 300,000	$ 925,000		$ 300,000	$ 925,000
License fee revenue			825,000	350,000	1,100,000
Paid upfront payment in cash								7,500,000
Issuance of common stock for acquired in-process research and development	27,500,000						27,500,000
Number of phase 2 clinical trials performed									2
Total upfront payment relating to acquired in-process research and development expensed		35,000,000								35,000,000
Shares of common stock issued against acquired in-process research and development							5,261,144
Number of days to be considered for closing price of common stock							5 days
Issuance of common stock for acquired in-process research and development	28,094,000						28,094,000
Acquired in-process research and development expense							594,000
Number of first evaluable patients with brain metastases in trial						30
Non-refundable upfront payment recognized in other income											$ 2,500,000